The Control of Parasites: the Role of Drugs1

Total Page:16

File Type:pdf, Size:1020Kb

The Control of Parasites: the Role of Drugs1 OF WASHINGTON, VOLUME 44, NUMBER 1, JANUARY 1977 17 Steinert, M., and A. B. Novikoff. 1960. The associated structures of Fasciola hepatica. existence of a cytostome and the occurrence Quart. J. Microsc. Sci. 104: 505-512. of pinocytosis in the trypanosome, Trypano- Thorsell, W., and N. Bjorkman. 1966. In soma mega. }. Biophys. Biochem. Cytol. 8: vitro studies on the effect of hexachlorophene 563-569. and its dimethylether on the liver fluke Fas- Sterling, C. R., and M. Aikawa. 1973. A ciola hepatica L. Z. Parasitenk. 28: 116- comparative study of gametocyte ultrastruc- 124. ture in avian Haemosporidia. J. Protozool. Van den Bossche, H., and P. A. J. Janssen. 20: 81-92. 1967. The biochemical mechanism of action Sterling, C. R., and D. L. DeGiusti. 1972. of the anthelmintic drug tetramisole. Life Ultrastructural aspects of schizogony, mature Sci. 6: 1781-1792. schizonts, and merozoites of Haemoproteus , and . 1969. Biochemical mech- metchnikovi. J. Parasit. 58: 641-652. anism of action of the antinematoclal drug Strufe, R., and R. Gonnert. 1967. Influence tetramisole. Biochem. Phannacol. 18: 35-42. of drugs on the metabolism of the tape- Vanderberg, J., J. Rhodin, and M. Yoeli. worm. Z. Tropenmed. Parasit. 18: 193-202. 1967. Electron microscopic and histochem- Terzakis, J. A., H. Sprinz, and R. A. Ward. ical studies of sporozoite formation in Plas- 1967. The transformation of the Plasmo- modium berghei. ]. Protozool. 14: 82-103. dium gallinaceum oocyst in Aedes aegypti Vickerman, K., and A. G. Luckins. 1969. Lo- mosquitoes. J. Cell Biol. 34: 311-326. calisation of variable antigens in the surface Theakston, R. D. G., and K. A. Fletcher. coat of Trypanosoma hrncei using ferritin- 197la. Electron cytochemical study of glu- conjugated antibody. Nature 224: 1125- cose-6-phosphate dehydrogenase activity in 1127. erythrocytes of malaria-infected mice, mon- Von Brand, T. 1973. Biochemistry of Para- keys and chickens. Life Sci. 10: 701-711. sites. 2nd ed. Academic Press, New York. •, and . 1971b. Ultrastructural lo- Yamao, Y. 1954. Histochemical studies on en- calization of NADH- and NADPH-dehydro- doparasites. V. distributions of the glycero- genases in the erythrocytic stages of the ro- monophosphates in the tissues of flukes, dent malaria parasite, Plasmodium berghei. Eurytrema coelomaticum, E. pancreaticum, Life Sci. 9: 421-428. Dicrocoeliiim lanceatum and Clonorchis sinen- Threadgold, L. T. 1963. The tegument and sis. J. Coll. Arts. Sci. Chiba Univ. 1: 9-13. The Control of Parasites: The Role of Drugs1 W. C. CAMPBELL Merck Institute for Therapeutic Research, Rahway, New Jersey 07065 ". the play is the tragedy 'Man', are the prevailing social and political forces in and its hero, the Conqueror Worm" the case of man, and the husbandry practices Edgar Allan Poe in the case of domestic animals. Of the mech- anisms invoked intentionally to reduce para- Poe's words were allegorical rather than sitism, biological control and vaccination have parasitological; but parasite control might be played roles that have been overshadowed by regarded, in large measure, as an attempt to the role of chemotherapy. It seems likely that strip the worm of its role as conqueror. antiparasitic drugs will continue to be of im- Undoubtedly the major extrinsic factors in portance for some time. determining the extent and degree of parasitism Antiparasitic drugs actually play many roles —not just because there are many drugs, but because one drug in its time plays many parts. Some are general roles—the parts played by Copyright © 2011, The Helminthological Society of Washington 18 PROCEEDINGS OF THE HELMINTHOLOGICAL SOCIETY Table 1. Productivity of Merino sheep from age Despite the very evident immunogenicity of 6 months to age 18 months (50 sheep per group, the infection, vaccination has not become a all groups grazed together). Anthelmintic B has significant means of control; and it has been broader spectrum than A, and greater activity the role of the antiparasitic drugs to make against immature worms. Both drugs were ad- ministered monthly. From Gordon, 1963. feasible the modern intensive production of an important food animal. % sheep of In helminthiasis we have to a lesser, but 70 Ih or % fleeces over at 18 Wool showing still significant extent, moved from the use of months per head defective drugs for the salvage of sick animals to the Treatment old Ib. wool prevention of disease. This is accomplished Controls — n o not by continuous chemoprophylaxis but by anthelmintic treatment 16 6.7 32 tactical treatment (administration of drugs Anthelmintic A 35 7.4 14 whenever local conditions make a buildup of Anthelmintic B 62 7.9 4 parasitism seem likely) or strategic treatment (administration of drugs according to a sched- ule based on the epidemiological conditions drugs in the overall scheme of parasite control prevailing in a given region). Quite suddenly, —and I shall say a little bit about those. There as these things go, we no longer hear of dev- are innumerable specific roles: this drug kills astating outbreaks of acute fascioliasis in the Haemonchus in sheep, that drug kills Ancylo- United Kingdom, or of haemonchosis in Aus- fitoma in man, and so on. I am not going to tralia. More important, perhaps, than the pre- say anything about those roles. They have been vention of overt disaster is the prevention of recounted many times in recent years. There the more subtle deleterious effects of parasitism are specific roles of another kind—the biochem- on the quantity and quality of livestock prod- ical roles. I do want to say something about ucts. In either case, anthelmintics, too, are those, partly because they are not often pulled currently playing the role of enhancer of agri- together in one place, but mostly because I cultural production. Obviously the increase in want to end by discussing how they might productivity is easy to demonstrate under con- relate to the discovery of tomorrow's anti- ditions favorable to clinical parasitism, and parasitic drugs. becomes more difficult and more controversial under conditions where parasitism is very much subclinical. An example of enhanced produc- The Role of Drugs in tivity may be found in the work of Gordon Livestock Parasitism (1963); some of his data are given in Table 1. Although I will be focusing attention on I want, however, to go beyond such well- helminth infections, the general role of drugs documented effects and to consider a more in controlling parasitic diseases in domestic recent and more comprehensive examination of animals is perhaps best illustrated by the the subject. situation in coccidiosis. Since the introduction Only in recent years have attempts been of medicated diets for the control of coccidiosis made to determine whether the increased pro- in 1948, it has been virtually axiomatic that an ductivity associated with drugs necessarily re- effective coccidiostat is indispensable for suc- sults in economic benefit. Just last month a cessful intensive production of chickens—this, paper appeared that is, I think, a striking ex- mind you, in a parasitic situation in which im- ample of how parasitological and economic munity to reinfection is easily demonstrated studies can be combined and focused on this under both experimental and field conditions. point (Anderson et al, 1976). These workers Indeed the natural immunological protection determined the economic returns from 2 is exploited in conjunction with chemo- strategic schemes of helminth control in therapy, and the poultryman, in this day of weaned lambs in Western Victoria, Australia; sophisticated agriculture, takes a great interest and they compared these with returns from in the degree to which a given coccidiostat flocks without a treatment scheme and, in part, will permit the development of natural im- with flocks subjected to unusually intensive munity, especially in replacement chickens. treatment. The economic analysis included Copyright © 2011, The Helminthological Society of Washington OF WASHINGTON, VOLUME 44, NUMBER 1, JANUARY 1977 19 Table 2. Maximum financial return (given favorable economic conditions) from flocks of lambs with no treatment schedule, a "traditional" strategic schedule, a "critical" strategic schedule, or an intense (biweekly) schedule. From Anderson, et al. 1976. Maximum return ( Australian dollars ) None Traditional Critical Intensive Gross return per 100 sheep 1029 1115 1205 1441 Net return per 100 sheep* 1023f 1097 1186 1271 Percent return on cost of treatment:!: — 617 1254 151 * Gross return minus cost of treatment. t Lambs received one treatment to control clinical parasitism. :j: Cost in addition to cost of single treatment in flocks with no treatment schedule. extrapolation of data to years in which eco- The Role of Drugs in nomic conditions were more favorable or less Parasitism of Man favorable than the year in which the data were collected. The figures in Tables 2 and 3 have First we must remember that antiparasitic been extracted from the wealth of information drugs have played, and continue to play, a life- in this paper to illustrate the following points. saving role. I seem to recall from some intro- (1) All schemes of anthelmintic treatment gave ductory textbook that visceral leishmaniasis better livestock production than no treatment was about 95% fatal before the introduction scheme, and thus a higher gross financial re- of antimonial drugs, and about 95% nonfatal turn. (2) Under favorable economic condi- afterwards. The lifesaving role of the anti- tions, all treatment schemes also gave a higher malarial drugs needs no elaboration. Control net return. Thus treatment always made eco- of morbidity on a population basis has also nomic sense, although the intensive (biweekly) been of importance in protozoal and helminthic treatment was not nearly so profitable as the infections, but it must be admitted that the more judicious schemes. (3) Under unfavor- overall success rate has been disappointingly able economic conditions, both strategic treat- low, and the need for effective strategic control ment schedules were economically advantage- remains distressingly great.
Recommended publications
  • 2002 FSIS National Residue Program, Section 4
    Table 4.1 Scoring Table for Veterinary Drugs 2002 FSIS NRP, Domestic Monitoring Plan COMPOUND/COMPOUND Historical Regula- With- Relative Predicted Predicted Impact Acute or Lack of Relative CLASS Testing tory drawal Number V = V, Except New & Chronic Testing Public Health Info. on Concern Time of (0.19437* When Existing Toxicity Info. on Concern Violations (CVM) (CVM) Animals R*N) + Actual V Human Con- Viola- Score = (FSIS) Treated 0.84625 is Disease cerns tions V*[(D+3*T)/4] (CVM) Available (CDC) (CVM) (FSIS) *{1+[(L- (V) (R) (W) (N) (D) (T) (L) 1)*0.05]} Those antibiotics quantitated by the 4 4 4 4 3.956 4.000 3 4 1 15.0 FSIS Bioassay MRM Amikacin (aminoglycoside) NT 3 4 2 2.012 2.012 3 2 4 5.2 Apramycin (aminoglycoside) NT 4 4 2 2.401 2.401 3 2 4 6.2 Kanamycin (aminoglycoside) NT 3 4 2 2.012 2.012 3 2 4 5.2 Spectinomycin (aminoglycoside) NA-D, M 4 4 3 3.179 3.179 3 2 4 8.2 Streptomycin (aminoglycoside) NA-D 4 4 3 3.179 3.179 3 2 4 8.2 Amoxicillin (beta-lactam) NT 3 2 2 2.012 2.012 3 4 4 8.7 Ampicillin (beta-lactam) NT 3 2 2 2.012 2.012 3 4 4 8.7 Cloxacillin (beta-lactam) NT 3 2 2 2.012 2.012 3 4 4 8.7 Hetacillin (beta-lactam) NT 2 2 2 1.624 1.624 3 4 4 7.0 Ticarcillin (beta-lactam) NT 2 2 2 1.624 1.624 3 4 4 7.0 Ceftiofur (cefalosporin) NT 3 2 3 2.596 2.596 4 2 4 7.5 Cefazolin (synthetic cefalosporin) NT 3 2 2 2.012 2.012 3 2 4 5.2 Chloramphenicol NA-N 4 2 1 1.624 1.624 4 4 4 7.5 Florfenicol (chloramphen.
    [Show full text]
  • Efficacy of Different Drugs in Treating Urinary Schistosomiasis
    Ecacy of Different Drugs in Treating Urinary Schistosomiasis: Systematic Review and Network Meta-analysis Huilong Fang XiangNan University Xuli Guo XiangNan University Chuwei Tang XiangNan University Fuchun Chen XiangNan University Ahmed Badr Menoua University Faculty of Medicine Feng Luo XiangNan University Junjie Wang ( [email protected] ) XiangNan University Systematic review update Keywords: Urinary schistosomiasis, Praziquantel, Artesunate, Metrifonate Posted Date: May 1st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-16780/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Background Praziquantel is the current pillar for morbidity control of schistosomiasis. Artesunate and its derivatives, widely used for malaria treatment, also display antischistosomal activities. This review compares the ecacy of three drugs, namely praziquantel (PZQ), artesunate, and metrifonate in urinary schistosomiasis. Methods Databases were searched for articles comparing the effectiveness of any of the three drugs to other medications or controls in urinary schistosomiasis in children aged 18 or less. Stata software was opted to generate the network meta-analysis. Ecacy (Cure rate and egg reduction rate) was the main outcome measure. Pairwise and network meta-analysis were used to report Odds Ratios (ORs) with either 95% condence interval (CI) for direct comparisons or 95% credible intervals (CrI) for indirect comparisons. Results The SUCRA plot for cure rate revealed that PZQ (SUCRA= 40.4%) was the fourth effective drug after albendazole 400mg (SUCRA= 71.5), metrifonate 5 mg (SUCRA= 62.2%), and metrifonate 10 mg (SUCRA= 59.7). PZQ was only superior to metrifonate 7.5 mg.
    [Show full text]
  • Anthelmintic Pyrvinium Pamoate Blocks Wnt/Β-Catenin and Induces Apoptosis in Multiple Myeloma Cells
    ONCOLOGY LETTERS 15: 5871-5878, 2018 Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells FANG XU1, YINGJIE ZHU1, YUHONG LU2, ZHI YU2, JUN ZHONG2, YANGQIU LI2 and JINGXUAN PAN1 1Jinan University Institute of Tumor Pharmacology, College of Pharmacy; 2Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R. China Received December 28, 2016; Accepted December 21, 2017 DOI: 10.3892/ol.2018.8006 Abstract. Multiple myeloma (MM) is a malignancy of the microenvironment components, such as bone marrow bone marrow. The median survival time of patients with stromal cells (4-6). MM is only 5 years, with patients frequently experiencing Although the introduction of thalidomide, lenalidomide relapse. Currently, there is no effective therapy for recurrent and bortezomib into the clinic has markedly improved MM. The results of the present study indicated that pyrvinium the response rates and survival in patients with MM (7), pamoate (PP), a US Food and Drug Administration-approved the disease remains largely incurable owing to relapse and oral anthelmintic drug, exhibited potent antitumor activity in drug resistance (8,9). Identifying novel agents to overcome MM cells in vitro. It is demonstrated that PP inhibited MM the adverse effects of current therapies remains an important cell proliferation and mediated apoptosis. Notably, PP mark- task in the clinic. edly promoted the degradation of β-catenin and abrogated The abnormal activation of the Wnt/β-catenin pathway its phosphorylation. PP triggered apoptosis in MM cells by in multiple types of cancer, including lymphomas and MM, inducing the release of cytochrome c and downregulating the makes it an attractive therapeutic target (10,11).
    [Show full text]
  • 2019-6654 Final Report of an Audit Carried out In
    Ref. Ares(2019)7826731 - 19/12/2019 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health and food audits and analysis DG(SANTE) 2019-6654 FINAL REPORT OF AN AUDIT CARRIED OUT IN BELARUS FROM 13 TO 24 MAY 2019 IN ORDER TO EVALUATE THE CONTROL OF RESIDUES AND CONTAMINANTS IN LIVE ANIMALS AND ANIMAL PRODUCTS INCLUDING CONTROLS ON VETERINARY MEDICINAL PRODUCTS Executive Summary This report describes the outcome of an audit carried out in Belarus from 13 to 24 May 2019 as part of the European Commission’s Directorate-General for Health and Food Safety planned work programme. The objective of the audit was to evaluate the effectiveness of official controls on residues and contaminants in live animals and animal products eligible for export to the European Union (EU). The audit assessed the implementation of the residue monitoring plan and also covered the authorisation, distribution and use of veterinary medicinal products, given that these areas have an impact on the monitoring of residues. Attention was also paid to examining the implementation of corrective actions indicated in response to specific recommendations made in the report of the previous residues audit to Belarus. The planning of the residue monitoring largely follows the principles of Directive 96/23/EC and covers for the most part an appropriate range of substances. The plan is nevertheless weakened by the fact that action levels for several substances across all commodities (including those for which listing has been requested) are not aligned with EU maximum residue limits, thus the plan would not be sufficient to demonstrate that commodities eligible for export to the EU would comply with such limits where they are lower that national limits.
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • United States Patent (19) 11) Patent Number: 5,001,115 Sloan (45) Date of Patent: Mar
    United States Patent (19) 11) Patent Number: 5,001,115 Sloan (45) Date of Patent: Mar. 19, 1991 54 PRODRUGS OF BIOLOGICALLY ACTIVE Primary Examiner-Mukund J. Shah HYDROXYAROMATIC COMPOUNDS Assistant Examiner-E. L. Ward Attorney, Agent, or Firm-Kerkam, Stowell, Kondracki (75 Inventor: Kenneth B. Sloan, Gainesville, Fla. & Clarke 73 Assignee: University of Florida, Gainesville, Fla, (57) ABSTRACT (21) Appl. No.: 352,919 Prodrugs of bio-active hydroxyaromatic drugs having 22 Filed: May 17, 1989 the structural formula: A pharmaceutically acceptable prodrug of a biologi (51] Int. Cl. ............... A61K 31/70; A61K 31/595; cally active, therapeutically effective hydroxyaromatic A61K 31/535; A61K 31/255 52 U.S. C. ..................................... 514/34: 514/289; drug, said prodrug being selected from the group con 514/169; 514/373; 514/222.8; 514/328; sisting of, (A) compounds having the structural for 514/360; 514/603; 514/417; 514/425; 514/518; mula: 546/44; 54.6/176; 546/75; 544/2; 536/64; 548/123; 548/209; 548/256; 548/417 DRUG-O-CR'R''-2) 58 Field of Search ............... 514/169,289, 373, 417, 514/425, 222.8, 328,360, 518, 603, 34; 536/64; wherein: 564/82, 155; 552/626; 546/44, 176, 75; 544/2; DRUG -O- is the hydroxyaromatic O-dehydro 548/123, 209, 256, 477, 595 residue of said drug; 56 References Cited R" and R' may be the same or different and may be H, PUBLICATIONS alkyl, aryl or electron withdrawing groups; 2 is a displaceable leaving group; and Katritzky, et al. J. Chem. Soc.
    [Show full text]
  • Swedres-Svarm 2004
    SVARM2004 Swedish Veterinary Antimicrobial Resistance Monitoring Preface .............................................................................................4 Summary ..........................................................................................6 Sammanfattning ...............................................................................7 Use of antimicrobials .........................................................................8 Resistance in zoonotic bacteria ......................................................12 Salmonella ..........................................................................................................12 Campylobacter ...................................................................................................15 Resistance in indicator bacteria ......................................................17 Escherichia coli ...................................................................................................17 Enterococcus .....................................................................................................20 Resistance in animal pathogens ......................................................28 Pig ......................................................................................................................28 Cattle ..................................................................................................................29 Horse ..................................................................................................................30
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
    [Show full text]